Browse by category

By integrating genetic findings from several of the world's largest biobanks, investigators from Mass General Brigham built metabolic a polygenic risk score (PRS) for predicting obesity and type 2 diabetes (T2D), which capture multiple genetic risk factors to provide an estimate for whether a person may develop a complex medical condition and how they might fare long-term, and outperformed existing disease-prediction models and predicted downstream morbidity and clinical inte

A Cleveland Clinic analysis of nearly 8,000 patients suggests that discontinuing semaglutide and tirzepatide, on average, does not lead to significant weight regain in clinical practice, as many patients later restart the original medication or try an alternative obesity treatment. In one of the largest real-world studies to date examining obesity treatment use and long-term weight changes after GLP-1 discontinuation, researchers at Cleveland Clinic found that many patients s

Olympus Corporation has launched the VISERA ELITE III surgical imaging platform designed to enhance surgical visualization, workflow efficiency and multispecialty flexibility, in the US. The VISERA ELITE III platform is a significant leap forward in surgical imaging and the third major co-developed product by SONY Olympus Medical (SOMED), a joint venture established in 2013. The VISERA ELITE III surgical imaging platform offers advanced features including Yellow Enhancement (

According to researcher from Ohio State University Wexner Medical Center in Columbus, prescription for patients who were eligible for metabolic and bariatric surgery (MBS) for glucagon-like peptide-1 receptor agonist (GLP-1 RA) increased from 2018 to 2025, while MBS use decreased beginning in 2023. “To our knowledge, this is the first study to provide evidence that trends in MBS use have not yet stabilised through quarter 3 of 2025,” the researchers noted. “Stratification by

Wegovy, a GLP-1 agonist for weight loss, may carry the highest risk of ischaemic optic neuropathy (ION) and sudden sight loss of the semaglutide drugs, according to a study by researchers from the University of Ottawa, Ottawa, Ontario, Canada. They found that the risk is almost five times higher with Wegovy than it is with Ozempic, and three times greater in men than it is in women. ION is caused by inadequate/interrupted blood flow to the optic nerve, resulting in sudden vis

Research presented at the 2026 Annual Meeting of the American Academy of Orthopaedic Surgeons (AAOS) has found that glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may be associated with improved short-term postoperative benefits, alongside possible long-term risks of osteoporosis, gout and osteomalacia compared with non-users. “We are just now reaching the precipice where five- and 10-year follow-up data are becoming available for patients taking GLP-1 medications,” sa